Recon Nq100 Cv Call (QYLD) 22.01 $QYLD Time for Buy

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Recon Nq100 Cv Call (QYLD) 22.01 $QYLD

Time for Buy Write ETFs?
Sweta Killa - Zacks Investment Research - Mon Feb 08, 9:10AM CST
In a sluggish backdrop, investors are looking to provide capital appreciation opportunities in the equity world with simultaneous downside protection. A gainful option for now could be the Buy-Write strategy.
HSPX: 45.04 (+0.13), QYLD: 22.01 (+0.05), PBP: 21.20 (+0.08), BWV: 67.83 (+0.31), VEGA: 27.25 (unch)

Yield Opportunity with a Covered Call ETF Strategy
ETFtrends.com - ETF Trends - Tue Dec 22, 3:30PM CST
With the equities market slowing down after a multi-year rally, investors may find opportunities in exchange traded funds that track buy-write or covered-call strategies. “Many investors overlook buy-write/covered call strategies, as their...
QQQ: 116.96 (+0.22), HSPX: 45.04 (+0.13), QYLD: 22.01 (+0.05), PBP: 21.20 (+0.08)

Recon Capital Partners Makes Change to the Recon Capital Nasdaq-100 Covered Call ETF (NASDAQ: QYLD) Index
BusinessWire - Wed Oct 14, 3:35PM CDT
Recon Capital Partners, the Greenwich, CT based provider of exchange traded funds (ETFs), has announced that after the close of trading on October 14, 2015, the Recon Capital Nasdaq-100 Covered Call ETF (NASDAQ: QYLD) will no longer be tracking the CBOE NASDAQ-100 BuyWrite Index (Symbol: BXN) and will begin tracking the CBOE NASDAQ-100 BuyWrite V2 Index (Symbol: BXNT).
QYLD: 22.01 (+0.05)

John Jacobs Joins Recon Capital Partners' Board
BusinessWire - Mon Oct 12, 12:00PM CDT
Veteran Nasdaq executive John Jacobs, whose experience includes creating the company's index business, has joined the Board of Trustees of Recon Capital Partners, the innovative exchange-traded fund (ETF) issuer behind the Nasdaq 100 Covered Call ETF (QYLD), the DAX Germany ETF (DAX) and the FTSE 100 ETF (UK).
DAX: 25.19 (+0.18), UK: 20.50 (+0.01), QYLD: 22.01 (+0.05)

Recon Capital Partners to Launch New ETF Platform
BusinessWire - Tue Sep 15, 8:05AM CDT
In an effort to develop and enhance its single-point-solution exchange traded fund (ETF) platform, Recon Capital Partners has turned to consulting firm Global ETF Advisors, led by industry veteran Richard Keary.
DAX: 25.19 (+0.18), UK: 20.50 (+0.01), QYLD: 22.01 (+0.05)

ETFs in Spotlight after Apple and Microsoft Earnings - ETF News And Commentary
Sweta Killa - ZACKS - Wed Jul 22, 4:15AM CDT
Investors should closely watch the movement in these ETFs having the largest exposure to Apple and Microsoft.
QQQ: 116.96 (+0.22), DGRW: 32.56 (+0.09), TDIV: 29.08 (+0.09), IXN: 108.18 (+0.25), XLK: 47.24 (+0.10), QYLD: 22.01 (+0.05), MSFT: 57.61 (+0.02), VGT: 118.61 (+0.28), AAPL: 107.06 (+0.33), IYW: 117.26 (+0.27)

Recon Capital Partners Enters Strategic Engagement with Brazilian RIA
BusinessWire - Mon Jun 01, 8:00AM CDT
Recon Capital Partners, the issuer behind the Recon Capital FTSE 100 ETF and the Recon Capital DAX Germany ETF, has increased its global distribution efforts and strengthened its commitment to continue delivering global investment solutions by partnering with Bullmark Financial Group, one of Brazil's fastest-growing RIA firms. The scope of the relationship will entail both firms collaborating on product development, enhancement and distribution with an emphasis on Latin American-themed exchange-traded products (ETPs) that mitigate risk via intelligent index construction.
DAX: 25.19 (+0.18), UK: 20.50 (+0.01), QYLD: 22.01 (+0.05)

Recon Capital Launches Only US-Listed ETF to Track London's FTSE 100
BusinessWire - Wed Apr 29, 7:30AM CDT
Recon Capital, the issuer behind the Recon Capital Nasdaq 100 Covered Call ETF and the Recon Capital DAX Germany ETF, has expanded its suite of products with the launch of the Recon Capital FTSE 100 ETF, the only U.S.-listed ETF benchmarked to the FTSE 100. The fund is slated to be available for trading on April 29, 2015.
DAX: 25.19 (+0.18), UK: 20.50 (+0.01), QYLD: 22.01 (+0.05), GSK: 44.25 (+1.27)

Options-Based ETFs Generate Better Risk-Adjusted Returns
ETFtrends.com - ETF Trends - Fri Feb 20, 9:30AM CST
Exchange traded funds that employ options have performed as well as the S&P 500 Index with lower volatility, providing investors with higher risk-adjusted returns. “Options-Based Funds had similar returns as the S&P 500 Index with...
FTHI: 20.28 (unch), FTLB: 20.04 (+0.13), HSPX: 45.04 (+0.13), HVPW: 19.73 (-0.04), QYLD: 22.01 (+0.05), PBP: 21.20 (+0.08)

Covered Call ETFs to Generate Yield in a Slow-Growth Environment
ETFtrends.com - ETF Trends - Fri Feb 13, 9:00AM CST
Equity investors should temper their expectations as earnings growth could slow this year. If we are in for a more sideways trending market, covered call exchange traded fund strategies could help generate attractive returns. There are a few...
SPY: 218.10 (+0.71), QQQ: 116.96 (+0.22), HSPX: 45.04 (+0.13), QYLD: 22.01 (+0.05), PBP: 21.20 (+0.08)

A Covered Call ETF Strategy Produces Big Yields
ETFtrends.com - ETF Trends - Fri Jan 30, 8:00AM CST
A little unknown exchange traded fund that follows a covered call strategy has generated robust dividend yields over its first year. The Recon Capital NASDAQ-100 Covered Call ETF (NasdaqGM: QYLD ) , which began trading on December 12, 2013, has...
QYLD: 22.01 (+0.05)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

SVRN Taps Industry Vet Patrick O'Kain as COO

Updated Category News Views 54

SVRN Aims for New Heights with a Savvy Hire If there’s one thing veteran market-watchers like myself know, it’s that leadership shifts can tell you more about a company’s guts than any press release. SVRN (NASDAQ: SVRN), a name with one foot firmly in the world of digital assets, just snagged Patrick O’Kain for their COO spot. They're not playing around, folks,...

Continue Reading
Survey Reveals 'TDS' Impact on 2026 Midterm Elections

Updated Category News Views 70

Midterms and 'Trump Derangement Syndrome': What's the Deal? Every election season there's something new to raise eyebrows, and this time it's 'Trump Derangement Syndrome' (TDS) taking the spotlight. After the dust of the 2026 mid-terms started settling, it turns out there's more than just traditional candidate bickering shaping votes. Can you guess what's driving voters?...

Continue Reading
Sempra Shines with Robust Q3 2026 Financials

Updated Category News Views 0

Strong Q3 Numbers Set the Scene It’s not every day you see a company cough up numbers that speak volumes. Sempra’s third quarter for 2026 paints a picture of solid performance, boasting earnings of $877 million or $1.34 per diluted share per GAAP standards. That’s an eye-opener compared to the paltry $77 million or $0.12 per share they reported same time last year....

Continue Reading
Coastal Financial Faces Class Action Suit Over Securities

Updated Category News Views 78

Securities Law Tangles: Coastal Financial Hits a Snag There's no dodging it—Coastal Financial Corporation's dogged by a class action lawsuit, and investors need to sit up and take notice. This kind of legal fracas can hit the stock price like a brick through a window, especially when alleged securities law violations crop up. DJS Law Group's got the reins on this one,...

Continue Reading
Grant Davis Joins Assembly Health as CXO

Updated Category News Views 101

Shuffling Pieces in Healthcare Management Change is constant in healthcare management, folks, and it's all about finding the right puzzle pieces. That's what Assembly Health has done by welcoming Grant Davis as their new Chief Experience Officer (CXO). Yeah, you heard me right. It's not a CEO or a CFO, but the CXO role that's under the spotlight this time around, aiming...

Continue Reading
MAURE's Three-Year Mark: Crafting Home Elegance

Updated Category News Views 53

Brooklyn's Gem: MAURE Turns Three Over in Brooklyn, there's a brand bubbling with style called MAURE. Now, we're talking three years strong, surviving the wild bout of the retail scene with a firm two feet planted in home and gifting. The Vision Turned Reality When Maureen Cavalieri, a hospitality veteran since 2009, first tossed this spark into the wind in 2023, it...

Continue Reading
Dizal Unveils Promising Data at ASH 2026

Updated Category News Views 72

Pushing the Horizons in Hematological Research From the bustling streets of Shanghai to the global stage of the ASH 2026, Dizal has made its mark again. This year's presentations could very well shake up the hematological landscape, showcasing new possibilities for treatment strategies. Golidocitinib: A Game-Changer? Now here's a ticket we've been watching with some high...

Continue Reading
LOA Roofing's Growth Recap Taps Southstone's Backing

Updated Category News Views 107

Pardon my skepticism, but when a roofing company names itself Life of Abundance, you know they're aiming to hit it big or at least make you think they're onto something special. LOA Roofing and Construction, holding its ground as a major player in the Central Texas market, set the stage for more ambitious growth. And they found themselves a dance partner in Southstone...

Continue Reading
SKF's Industrial Push: Energy Efficiency at COP31

Updated Category News Views 17

SKF's Green Initiative: A Major Step Forward You ever find yourself in a room full of big players, each trying to outdo the other? That's the stage set for SKF at COP31, where they're not just strutting around showing off but actually offering some substance—a rarity in these highbrow gatherings. They're juicing up the talk around energy efficiency and circularity...

Continue Reading
Eli Lilly's Retatrutide Trials Signal Innovation

Updated Category News Views 48

Unpacking Lilly's Latest Rheumatology Innovations Lilly's taking the stage at ACR Convergence 2026 with a potent arsenal of data that’s got folks buzzing. The company’s put the pedal to the metal on understanding the intertwining chords of obesity and rheumatologic conditions, and boy, are they not messing around. Retatrutide: A Triple Threat in the Making Headlining...

Continue Reading

Top 5 Most Recently Viewed Articles

SKYX Technologies Expands Market Presence with Insider Investments

Updated Category News Views 166

SKYX Technologies' Corporate Developments SKYX Technologies, also known as SKYX (NASDAQ: SKYX), is taking significant strides in the smart technology sector. This dynamic company focuses on transforming homes and buildings into smarter, safer, and more advanced spaces. With a remarkable portfolio of over 97 issued and pending patents, SKYX aims to set a new standard in...

Continue Reading
Crinetics Pharmaceuticals Expands Workforce With Stock Options

Updated Category News Views 195

Crinetics Pharmaceuticals Enhances Employee Incentives In a recent announcement, Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX), based in San Diego, revealed a significant step in enhancing employee incentives and strengthening its workforce. On October 10, 2025, the company’s Compensation Committee authorized the granting of stock options and restricted stock units...

Continue Reading
Manulife Investment Management Earns Top Recognition in Sustainable Finance

Updated Category News Views 199

Manulife Investment Management Recognized for Excellence In a significant acknowledgment of its leadership in sustainable finance, Manulife Investment Management (Manulife IM) has made it to the prestigious list of IPE Real Assets' Top 50 Natural Capital Managers. This recognition comes as the firm is gearing up for robust fundraising activities, with an exciting fund...

Continue Reading
Vaxart Reports Progress and Financial Performance for Q3 2025

Updated Category News Views 213

Vaxart’s Business Progress and Financial Results Overview Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company, recently provided a significant update on its business and reported its financial outcomes for the third quarter of 2025. This latest communication showcases exciting developments in their oral recombinant vaccine platform, which is designed to...

Continue Reading
Madrigal Pharmaceuticals Marks Enrollment Milestone in NASH Study

Updated Category News Views 47

Madrigal Pharmaceuticals Achieves Enrollment Milestone in NASH Study Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company dedicated to developing innovative therapies for liver diseases, has announced a significant milestone in their MAESTRO-NASH OUTCOMES clinical trial. This study evaluates the efficacy of resmetirom in patients diagnosed with...

Continue Reading